Defendant
10 cases as defendant.
Genevant Sciences GmbH is a Swiss-incorporated nucleic acid delivery company headquartered at Viaduktstrasse 8, Basel, Switzerland, with affiliated offices in Cambridge, Massachusetts and Vancouver/Burnaby, British Columbia. It was launched in April 2018 as a jointly owned venture between Roivant Sciences and Arbutus Biopharma. Genevant Sciences GmbH is an indirect subsidiary of Genevant Sciences Ltd.; as of mid-2026 Roivant Sciences Ltd. (Nasdaq: ROIV) held roughly 83% and Arbutus Biopharma (Nasdaq: ABUS) about 16% of Genevant Sciences Ltd. Headcount and standalone revenue figures are not disclosed in public sources.
Genevant is an operating technology company, not a shell. Its business is lipid nanoparticle (LNP) and ligand-conjugate (GalNAc) delivery technology for RNA-based medicines — mRNA, RNAi and gene-editing payloads. Under an April 2018 cross-license with Arbutus, it holds an exclusive, sublicensable worldwide license to Arbutus's LNP and GalNAc patent estate for all fields other than hepatitis B virus and certain exclusions, and it sublicenses that technology to partners and pursues its own RNA programs. Arbutus's LNP platform (125+ international patent families) is used in Alnylam's Onpattro (patisiran).
Genevant is an active two-way litigant, consistent with its case data (4 as plaintiff, 10 as defendant). It is the co-plaintiff with Arbutus in LNP enforcement suits against COVID-19 vaccine makers, and a defendant in Acuitas Therapeutics' 2022 patent suits (S.D.N.Y., D.N.J.) concerning LNP technology. Its affirmative cases have been filed in the District of Delaware and the District of New Jersey rather than the Eastern District of Texas.
Most prominent: Arbutus/Genevant v. Moderna (D. Del., filed Feb. 2022), resolved in March 2026 by a global settlement of up to $2.25 billion ($950 million upfront plus a contingent $1.3 billion), with Moderna consenting to judgments of infringement and no invalidity on four patents. Arbutus/Genevant v. Pfizer and BioNTech (D.N.J., filed April 2023) remains pending, with related Canadian and Unified Patent Court actions added in 2026.
Moderna's appeal from the District of Delaware action, primarily raising its 28 U.S.C. § 1498 government-contractor immunity defense. US 8,822,668 is tagged to the appeal via the underlying docket, but the appeal concerns the four patents actually adjudicated.
Acuitas refiled its declaratory-judgment action against Genevant and Arbutus in D.N.J. on August 4, 2023, again seeking declarations that Comirnaty does not infringe and that ten Arbutus patents are invalid. The narrative could not verify the D.N.J. case number; a possible 3:23-cv-04200 identification was expressly treated as unverified.
Acuitas filed a declaratory-judgment action against Genevant and Arbutus in the Southern District of New York concerning Comirnaty; US 8,822,668 was among the patents at issue. The action was voluntarily dismissed without prejudice on August 4, 2023, and Acuitas refiled in New Jersey.
Acuitas filed a declaratory-judgment action for non-infringement and invalidity against Genevant and Arbutus in S.D.N.Y., challenging nine Arbutus patents including 11141378. The action was voluntarily dismissed without prejudice on August 4, 2023.
Acuitas filed a declaratory judgment action in S.D.N.Y. on March 18, 2022 against Genevant and Arbutus, seeking declarations that Comirnaty does not infringe and that nine Arbutus/Genevant patents, expressly including U.S. 8,058,069, are invalid. Acuitas voluntarily dismissed without prejudice on Aug. 4, 2023; the case terminated Aug. 7, 2023, and Acuitas refiled in D.N.J.
Acuitas Therapeutics filed a declaratory judgment action for non-infringement and invalidity against Arbutus Biopharma and Genevant Sciences regarding the Arbutus patent estate, with US 9,518,272 listed among the patents flagged for the docket. The case was voluntarily dismissed without prejudice on August 4, 2023, and Acuitas refiled in New Jersey.
Acuitas Therapeutics filed a declaratory judgment action in the Southern District of New York against Genevant Sciences GmbH and Arbutus Biopharma Corp., seeking non-infringement and invalidity of Arbutus patents including U.S. Patent No. 9,006,417, in connection with the Pfizer/BioNTech COVID-19 vaccine COMIRNATY and Acuitas's LNP technology. Acuitas voluntarily dismissed the action without prejudice on August 4, 2023, and it was terminated August 7, 2023, coinciding with refiling in New Jersey.
Acuitas filed a declaratory-judgment action in S.D.N.Y. seeking declarations that Comirnaty does not infringe and nine Arbutus/Genevant patents are invalid; the '320 patent was identified in a June 3, 2022 notice. After a motion to dismiss, Acuitas amended and then voluntarily dismissed the action and refiled in D.N.J.
Reported but unconfirmed D.N.J. declaratory-judgment action by Acuitas against Arbutus and Genevant, challenging a list of patents including 11141378 and other Arbutus family patents. The narrative could not independently verify the case number 3:23-cv-04200 against the Acuitas caption.
Earlier New York declaratory judgment action by Acuitas against Genevant (et al.) listed on the '435 patent's litigation linkage. It was withdrawn/not pursued in New York, and Acuitas refiled the declaratory judgment action in New Jersey (3:23-cv-04200).